Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Speech therapy beneficial to patients with supragastric belching

10 Oct 2018

Speech therapy may effectively reduce excessive supragastric belching, according to a study. This treatment is aimed at increasing awareness of air inhalation and injection manoeuvres, as well as performing exercises to enhance abdominal, quiet and fluent breathing (without sudden stops).

A total of 73 patients with supragastric belching underwent speech therapy, among whom 48 were included in the analysis. Therapy comprised five components: explanation of the supragastric belching mechanism, promotion of awareness of oesophageal air influx, exercises to improve breathing, enhancement of lingual–laryngeal–cricopharyngeal complex functioning and implementation into daily life.

Supragastric belching was proven by 24-hour impedance measurements in 30 patients and diagnosed by an experienced speech language pathologist in 18 patients. The median symptom duration at the start of therapy was 2 years.

Speech therapy yielded significant reductions in the symptoms of supragastric belching, with efficacy evaluated using visual analogue scale (VAS) scores. Total median VAS score was 406 (291–463) prior to treatment vs 125 (17–197) following treatment.

Sufficient-to-major improvements were achieved in 40 patients (83 percent) over a median therapy duration of 3 months and 10 sessions.

The present data demonstrate the clinical importance of speech therapy in patients with excessive supragastric belching, researchers said. Among the main focuses of therapy are the frequent strained mouth and/or glottal closures.

While the method by which the patient relaxes the upper oesophageal sphincter (UES) at the moment of air influx is not clearly understood, researchers postulated that higher pharyngeal pressure, in case of air injection, could open the oesophageal sphincter. Additionally, the tight and abrupt laryngeal and vocal folds closure plays a role in the initiation of the supragastric air influx.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.